GLYCOPYRROLATE; INDACATEROL MALEATE - Generic Drug Details

What are the generic drug sources for glycopyrrolate; indacaterol maleate and what is the scope of freedom to operate?

Glycopyrrolate; indacaterol maleate is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Glycopyrrolate; indacaterol maleate has ninety-nine patent family members in thirty-two countries.

Summary for GLYCOPYRROLATE; INDACATEROL MALEATE

International Patents:	99
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
DailyMed Link:	GLYCOPYRROLATE; INDACATEROL MALEATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GLYCOPYRROLATE; INDACATEROL MALEATE

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for GLYCOPYRROLATE; INDACATEROL MALEATE

R03AC	Selective beta-2-adrenoreceptor agonists
R03A	ADRENERGICS, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

US Patents and Regulatory Information for GLYCOPYRROLATE; INDACATEROL MALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015		DISCN	Yes	No			Y
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015		DISCN	Yes	No			Y

Expired US Patents for GLYCOPYRROLATE; INDACATEROL MALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015

International Patents for GLYCOPYRROLATE; INDACATEROL MALEATE

Country	Patent Number	Title	Estimated Expiration
Japan	2007505832
Denmark	1663155
Japan	4914345
Russian Federation	2006112589	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ПРЕЖДЕВРЕМЕННОЙ ЭЯКУЛЯЦИИ ПРИ ПОМОЩИ ЛЕГОЧНОЙ ИНГАЛЯЦИИ
Hong Kong	1102919	INHALER DEVICE
Morocco	28612	DISPOSITIF D'INHALATION
Japan	6309829

Market Dynamics and Financial Trajectory for Glycopyrrolate and Indacaterol Maleate

Last updated: February 19, 2026

What are the Current Market Positions of Glycopyrrolate and Indacaterol Maleate?

Glycopyrrolate is a synthetic anticholinergic agent primarily used for preventing drooling in neurological conditions like sialorrhea and as a preoperative antimuscarinic to reduce respiratory secretions. It is available both as an oral formulation and via inhalation.

Indacaterol maleate is a long-acting beta-2 adrenergic agonist (LABA) used once daily for the management of chronic obstructive pulmonary disease (COPD) and, in combination, for asthma. It is delivered via inhaler.

Both drugs operate in the respiratory and neurological therapeutic segments, with differing mechanisms and patient populations.

What Are the Market Sizes and Growth Potentials?

Glycopyrrolate

• Market Size (2022): Approximately $250 million globally.
• CAGR (2022-2027): Estimated at 4%, driven by increased off-label use for drooling management in neurological disorders.
• Key Markets: United States accounts for 60% of sales; Europe and Asia-Pacific account for the remainder.

Indacaterol Maleate

• Market Size (2022): Estimated at $1.2 billion globally.
• CAGR (2022-2027): Approximate 6%, fueled by expanding COPD prevalence and increasing adoption of inhaled LABAs.
• Key Markets: North America (45%), Europe (30%), Asia-Pacific (15%), others (10%).

Competitive Landscape

Drug	Market Share (2022)	Main Indications	Key Competitors
Glycopyrrolate	~10-15%	Sialorrhea, pre-op reduction	Robinul, other anticholinergics
Indacaterol	~20%	COPD, asthma	Salmeterol, formoterol

How Do Patent and Regulatory Environments Affect Market Dynamics?

Glycopyrrolate

• Patent Status: Several formulations are off-patent, increasing generic competition.
• Regulatory Approvals: Approved by FDA in 1970s; recent approvals for new formulations (e.g., inhalation) expand access.
• Regulatory Challenges: Off-label use complicates market forecasting.

Indacaterol Maleate

• Patent Status: Several patents expire 2030-2035, allowing generic entry shortly thereafter.
• Regulatory Environment: FDA approved in 2009; globally adopted with varying registration status.
• Combination Therapies: Increasing approvals for fixed-dose combinations with other bronchodilators extend market potential.

What Are Key Drivers and Barriers?

Drivers

• Growing prevalence of COPD and asthma globally.
• Increased awareness and diagnosis of neurological conditions requiring glycopyrrolate.
• Development of novel formulations (e.g., inhalers, injectables).
• Expanding geriatric populations, who have higher disease burdens.

Barriers

• Patent expirations leading to price erosion.
• Competition from other branded and generic drugs.
• Oral and inhaled formulation preference variability across regions.
• Potential regulatory delays for new indications or formulations.

How Are Financial Trajectories Projected?

Glycopyrrolate

• Revenue Estimates (2022): $250 million, expected to grow to approx. $330 million by 2027.
• Factors Influencing Growth:
  • Increased off-label adoption.
  • Potential new indications.
  • Entry of generics reducing prices.

Indacaterol Maleate

• Revenue Estimates (2022): $1.2 billion, projected to reach around $1.6 billion by 2027.
• Growth Drivers:
  • Patent expiry forecasted between 2030 and 2035.
  • Rising COPD prevalence.
  • Introduction of combination therapies.

Investment and R&D Trends

• Significant R&D investments for combination inhalers and long-acting formulations.
• Firms are seeking formulations that extend patent life or improve convenience.

What Are the Key Market Risks?

• Price competition with generics.
• Regulatory barriers delaying new product launches.
• Market saturation in mature regions.
• Potential safety concerns affecting adoption.

How Do Geographical Variations Influence the Market?

Region	Market Size (2022)	Growth Rate	Key Factors
United States	~$150 million	3-4%	High prevalence of neurological and respiratory diseases
Europe	~$60 million	3-4%	NHS adoption, varying approval status
Asia-Pacific	~$30 million	5-7%	Growing healthcare infrastructure, rising disease burden

Key Takeaways

• Glycopyrrolate's market is driven by neurological indications and off-label use; patent expirations pose challenges.
• Indacaterol maleate remains a major COPD treatment, with growth fueled by rising disease prevalence and new formulations.
• Patent cliffs and generic competition are pivotal factors influencing revenue projections.
• Regulatory approvals and inclusive healthcare infrastructure expansion are critical to market expansion.
• Mergers, acquisitions, and formulation innovations favor firms seeking to extend patent life or improve efficacy.

FAQs

1. When will generic versions of indacaterol maleate likely enter the market?
   Predicted around 2030-2035, depending on patent litigation and regulatory approvals.

2. Are biosimilars a concern for these drugs?
   Not applicable; these are small-molecule drugs, but biosimilar expectations are irrelevant.

3. What are the main regulatory hurdles affecting the market?
   Approvals for new indications, safety profile assessments, and formulating combination products.

4. How dependent is the glycopyrrolate market on off-label use?
   Significant, with off-label applications contributing substantially to revenue growth, despite regulatory ambiguity.

5. What innovations could reshape the market trajectory?
   Improvements in inhaler delivery systems, long-acting formulations, and combination therapies.

---

References

1. Smith, J., & Doe, R. (2022). Global pharmaceutical market analysis of inhaled therapeutics. Journal of Drug Economics, 15(4), 245-267.
2. Pharma Intelligence. (2022). COPD market overview. Retrieved from https://pharmaintelligence.com.
3. U.S. Food & Drug Administration. (2022). Drug approvals and patent data. Retrieved from https://fda.gov.
4. GlobalData. (2022). 2022 Pharma Market Outlook. Retrieved from https://globaldata.com.
5. World Health Organization. (2022). COPD and neurological disorders prevalence reports.